Lyell Immunopharma (Lyell Immunopharma) Gross-Profit-to-Asset % : 0.01% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is Lyell Immunopharma Gross-Profit-to-Asset %?

Gross-Profit-to-Asset % is calculated as Gross Profit divided by its average Total Assets over a certain period of time. Lyell Immunopharma's annualized Gross Profit for the quarter that ended in Dec. 2023 was $0.05 Mil. Lyell Immunopharma's average Total Assets over the quarter that ended in Dec. 2023 was $772.51 Mil. Therefore, Lyell Immunopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 was 0.01%.

Lyell Immunopharma Gross-Profit-to-Asset % Historical Data

The historical data trend for Lyell Immunopharma's Gross-Profit-to-Asset % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Lyell Immunopharma Gross-Profit-to-Asset % Chart

Lyell Immunopharma Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Gross-Profit-to-Asset %

0.12

1.06

1.05

8.20

0.02

Lyell Immunopharma Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Gross-Profit-to-Asset %	Get a 7-Day Free Trial												20.22	0.03	0.01	0.01	0.01

Competitive Comparison of Lyell Immunopharma's Gross-Profit-to-Asset %

For the Biotechnology subindustry, Lyell Immunopharma's Gross-Profit-to-Asset %, along with its competitors' market caps and Gross-Profit-to-Asset % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Lyell Immunopharma's Gross-Profit-to-Asset % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Lyell Immunopharma's Gross-Profit-to-Asset % distribution charts can be found below:

* The bar in red indicates where Lyell Immunopharma's Gross-Profit-to-Asset % falls into.

Lyell Immunopharma Gross-Profit-to-Asset % Calculation

Lyell Immunopharma's annualized Gross-Profit-to-Asset % for the fiscal year that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (A: Dec. 2023 )	/	( (Total Assets (A: Dec. 2022 )	+	Total Assets (A: Dec. 2023 ))	/ count )
	=	0.13	/	( (937.561	+	750.029)	/ 2 )
	=	0.13	/	843.795
	=	0.02 %

Lyell Immunopharma's annualized Gross-Profit-to-Asset % for the quarter that ended in Dec. 2023 is calculated as:

Gross-Profit-to-Asset %	=	Gross Profit (Q: Dec. 2023 )	/	( (Total Assets (Q: Sep. 2023 )	+	Total Assets (Q: Dec. 2023 ))	/ count )
	=	0.052	/	( (794.989	+	750.029)	/ 2 )
	=	0.052	/	772.509
	=	0.01 %

In the calculation of annual Gross-Profit-to-Asset %, the Gross Profit of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Gross Profit data used here is four times the quarterly (Dec. 2023) data. Gross-Profit-to-Asset % is displayed in the 30-year financial page.

Lyell Immunopharma Gross-Profit-to-Asset % Related Terms

Thank you for viewing the detailed overview of Lyell Immunopharma's Gross-Profit-to-Asset % provided by GuruFocus.com. Please click on the following links to see related term pages.

Lyell Immunopharma (Lyell Immunopharma) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Lyell Immunopharma Inc (NAS:LYEL) » Definitions » Gross-Profit-to-Asset %

Comparable Companies

Traded in Other Exchanges

N/A

Address

201 Haskins Way, South San Francisco, CA, USA, 94080

Website

https://www.lyell.com

Lyell Immunopharma Inc is a T cell reprogramming company dedicated towards the mastery of T cells to eradicate solid tumors. Its pipeline includes CARs (Chimeric antigen receptors), TILs (Tumor-infiltrating lymphocytes), and TCRs (T cell receptors).

Executives

Richard Klausner	director, officer: Executive Chairman	5200 ILLUMINA WAY, SAN DIEGO CA 92122
Matthew Lang	officer: Chief Business Officer	C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005
Rahsaan Thompson	officer: Chief Legal Officer	233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Tina M. Albertson	officer: Chief Medical Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Gary K. Lee	officer: Chief Scientific Officer	C/O LYELL IMMUNOPHARMA, INC., 201 HASKINS WAY, SOUTH SAN FRANCISCO CA 94080
Cathy Friedman	director	C/O INNOVIVA, INC., 2000 SIERRA POINT PARKWAY, SUITE 500, BRISBANE CA 94005
Arch Venture Fund Ix Overage, L.p.	10 percent owner	8725 W. HIGGINS ROAD, SUITE 290, CHICAGO IL 60631
Elizabeth Homans	director, officer: Chief Executive Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Stephen J. Hill	officer: Chief Technical Ops. Officer	C/O LYELL IMMUNOPHARMA, INC., 400 EAST JAMIE COURT, SUITE 301, SOUTH SAN FRANCISCO CA 94080
Charles W. Newton	officer: Chief Financial Officer	46 FREDRICK AVENUE, ATHERTON CA 94027
Otis W Brawley	director	5203 BRISTOL INDUSTRIAL WAY, BUFORD GA 30518
Elizabeth G Nabel	director	BRIGHAM AND WOMEN'S HOSPITAL, 75 FRANCIS ST, BOSTON MA 02115
William Jl Rieflin	director	NGM BIOPHARMACEUTICALS, INC., 333 OYSTER POINT BLVD., SOUTH SAN FRANCISCO CA 94080
Arch Venture Partners Ix, Llc	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
Arch Venture Partners Ix, L.p.	10 percent owner	8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631